B+
Bull case
25%
Probability
Target price
$4.25
+82.4% vs current
PLX
Protalix BiotherapeuticsANYSE American / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$2.85
+22.3% vs current
B-
Bear case
25%
Probability
Target price
$1.55
-33.5% vs current
AI sentiment snapshot
Latest data as of 2026-07-18
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+66.3
Score
AI commentary
News tone is mildly positive, driven by the May earnings update, milestone receipt, reaffirmed guidance, and pipeline progress. Coverage is thin, with no usable social, options, short-interest, or analyst-revision data in the packet; confidence therefore remains capped despite strong primary-source context [#SEC-8K-2026-05-13].
RankAlpha Sentiment Codex - 2026-07-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-30catalystElfabrio reimbursement conversion and second-half sales updateHigh impact
The European Commission’s every-four-weeks dosing approval triggered a $25 million Chiesi milestone. Protalix reaffirmed 2026 revenue guidance of $78-$83 million, with commercial impact expected mainly in the second half as country-level reimbursement approvals progress [#SEC-8K-2026-05-13].
2026-12-31eventPRX-115 Phase 2 enrollment completionHigh impact
The RELEASE Phase 2 study continues enrolling, with completion targeted by year-end 2026. Slippage would likely weigh on this event-driven biotech valuation [#SEC-8K-2026-05-13].
2027-09-30catalystPRX-115 Phase 2 top-line resultsHigh impact
Top-line results are anticipated in the second half of 2027, representing the clearest potential clinical rerating event but also a binary outcome with substantial execution and efficacy risk [#SEC-8K-2026-05-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology